ENVB (Enveric Biosciences) Change In Inventory : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Enveric Biosciences Change In Inventory?

Enveric Biosciences's change in inventory for the quarter that ended in Sep. 2024 was $0.00 Mil. It means Enveric Biosciences's inventory stayed the same from Jun. 2024 to Sep. 2024 .

Enveric Biosciences's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Enveric Biosciences's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Enveric Biosciences's Total Inventories for the quarter that ended in Sep. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Enveric Biosciences Change In Inventory Historical Data

The historical data trend for Enveric Biosciences's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences Change In Inventory Chart

Enveric Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

Enveric Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Enveric Biosciences Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Enveric Biosciences (NAS:ENVB) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Enveric Biosciences's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Enveric Biosciences's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Enveric Biosciences's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Enveric Biosciences Change In Inventory Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Enveric Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (NAS:ENVB) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

SLZA:Germany

Address

4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103

Website

https://www.enveric.com

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.

Executives

Frank Pasqualone	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kevin Michael Coveney	officer: Chief Financial Officer	10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606
Robert Iv Dickey	officer: Chief Financial Officer	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bevin O'neil	director	C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103
Michael D Webb	director	C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Bradley George Thompson	director	1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9
Jillian Marie Hagel	officer: Chief Technical Officer	3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8
Joseph Edward Tucker	director, officer: Chief Executive Officer	3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8
Peter J. Facchini	officer: Chief Scientific Officer	155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1
Carter Julian Ward	officer: Chief Financial Officer	165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Lind	director
Marcus Schabacker	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Solomon Mayer	director	150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019
David Ian Johnson	director, officer: CEO and Chairman	C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Robert G. Wilkins	officer: Chief Medical Officer	C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103